Abstract
Co-occurring pathological mutations in non-small cell lung cancer (NSCLC) may account for clinical heterogeneity not explained by the single driver mutation model. The prognostic significance of various co-mutations and adjuvant treatment modalities has been explored in early-stage NSCLC, but there has not been a focus on the impact of smoking and EGFR co-mutations in early-stage NSCLC. This study aims to characterize the frequency of co-mutations in EGFR-mutated (EGFRm) early-stage resected NSCLC; to describe relationships between smoking history and co-mutation status; and to determine whether prognosis differs by co-mutation status and smoking status among patients with EGFRm NSCLC.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.